Jump to content

2C-CN

Add links
From Wikipedia, the free encyclopedia

2C-CN
Clinical data
Other names25CN; 2,5-Dimethoxy-4-cyanophenethylamine; 4-Cyano-2,5-dimethoxyphenethylamine
Identifiers
  • 4-(2-aminoethyl)-2,5-dimethoxybenzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC11H14N2O2
Molar mass206.245 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)C#N
  • InChI=1S/C11H14N2O2/c1-14-10-6-9(7-13)11(15-2)5-8(10)3-4-12/h5-6H,3-4,12H2,1-2H3
  • Key:OGWCKYKYGQORLF-UHFFFAOYSA-N

2C-CN, also known as 4-cyano-2,5-dimethoxyphenethylamine, is a chemical compound of the phenethylamine and 2C families.[1][2][3][4][5][6] It was not known to have been tested in humans and it is unknown whether it produces psychedelic effects.[1][2] According to Daniel Trachsel however, 2C-CN was inactive at an oral dose of 10 mg, whereas an oral dose of 22 mg possibly produced threshold effects.[7]

The drug is the 2C parent compound of potent serotonin 5-HT2A receptor agonists of the 25-NB family including 25CN-NBOH, 25CN-NBOMe, 25CN-NBF, and 25CN-NBMD, among others.[8][9][10][6][11][12] 25CN-NBOH is notable in being one of the most selective serotonin 5-HT2A receptor agonists known.[8][11] In addition, 25-NB derivatives of 2C-CN are known that act as β-arrestin-biased serotonin 5-HT2A receptor agonists.[6]

2C-CN was first described in the scientific literature by 1984.[3] It was briefly mentioned by Alexander Shulgin in his books PiHKAL (Phenethylamines I Have Known and Loved) (1991) and The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds (2011).[1][2]

See also

[edit]

References

[edit]
  1. ^ a b c Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. "The treatment of the 2C-B phthalimide described above, with cuprous cyanide rather than cuprous chloride, gave rise to the cyano analog which, on hydrolysis with hydrazine, yielded 2,5-dimethoxy-4-cyanophenethylamine (2C-CN). Hydrolysis of this with hot, strong base gave the corresponding acid, 2,5-dimethoxy-4-carboxyphenethylamine, 2C-COOH. No evaluation of either of these compounds has been made in the human animal, as far as I know."
  2. ^ a b c Shulgin A, Manning T, Daley PF (2011). "#55. DOCN". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 105–106. ISBN 978-0-9630096-3-0. OCLC 709667010.
  3. ^ a b Cheng AC, Castagnoli N (April 1984). "Synthesis and physicochemical and neurotoxicity studies of 1-(4-substituted-2,5-dihydroxyphenyl)-2-aminoethane analogues of 6-hydroxydopamine". Journal of Medicinal Chemistry. 27 (4): 513–520. doi:10.1021/jm00370a014. PMID 6423824.
  4. ^ Leth-Petersen S, Bundgaard C, Hansen M, Carnerup MA, Kehler J, Kristensen JL (October 2014). "Correlating the metabolic stability of psychedelic 5-HT₂A agonists with anecdotal reports of human oral bioavailability". Neurochemical Research. 39 (10): 2018–2023. doi:10.1007/s11064-014-1253-y. PMID 24519542.
  5. ^ Märcher-Rørsted E, Nykodemová J, Kristensen JL (April 2021). "An improved, scalable synthesis of the selective serotonin 2A receptor agonist 25CN-NBOH". Synopen. 5 (2): 158–160. doi:10.1055/a-1524-4439.
  6. ^ a b c Poulie CB, Pottie E, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, et al. (September 2022). "Discovery of β-Arrestin-Biased 25CN-NBOH-Derived 5-HT2A Receptor Agonists". Journal of Medicinal Chemistry. 65 (18): 12031–12043. doi:10.1021/acs.jmedchem.2c00702. PMC 9511481. PMID 36099411.
  7. ^ Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Retrieved 31 January 2025. Die Substanz 2C-CN (186) [87] trägt eine Nitrilgruppe in der 4-Position. Aufgrund der polaren Nitrilgruppe und den tieferen Affinitäten des 3C-Analogons DOCN (187) zum 5-HT2A-Rezeptor (siehe Tabelle 10) kann eine schwache Aktivität im Menschen vermutet werden. Das deckt sich mit ersten Versuchen am Menschen, wonach 10mg 2C-CN (186) oral keinerlei Effekte zeigten und 22mg lediglich als mögliche Schwellendosis bezeichnet wurden.
  8. ^ a b Märcher Rørsted E, Jensen AA, Kristensen JL (November 2021). "25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor". ChemMedChem. 16 (21): 3263–3270. doi:10.1002/cmdc.202100395. PMID 34288515.
  9. ^ Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, et al. (June 2017). "Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of N-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist". The Journal of Pharmacology and Experimental Therapeutics. 361 (3): 441–453. doi:10.1124/jpet.117.239905. PMID 28360333.
  10. ^ Jensen AA, Halberstadt AL, Märcher-Rørsted E, Odland AU, Chatha M, Speth N, et al. (July 2020). "The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH". Biochemical Pharmacology. 177: 113979. doi:10.1016/j.bcp.2020.113979. PMID 32298690.
  11. ^ a b Poulie CB, Jensen AA, Halberstadt AL, Kristensen JL (December 2020). "DARK Classics in Chemical Neuroscience: NBOMes". ACS Chemical Neuroscience. 11 (23): 3860–3869. doi:10.1021/acschemneuro.9b00528. PMC 9191638. PMID 31657895.
  12. ^ Slocum ST, DiBerto JF, Roth BL (July 2022). "Molecular insights into psychedelic drug action". Journal of Neurochemistry. 162 (1): 24–38. doi:10.1111/jnc.15540. PMID 34797943.
[edit]



Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=2C-CN&oldid=1296620768"